Cellect Biotechnology logo

APOP - Cellect Biotechnology News Story

$2.74 0.0  0.4%

Last Trade - 15/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £4.60m
Enterprise Value £84.6k
Revenue £n/a
Position in Universe 6086th / 6547

BRIEF-Cellect Biotechnology Initiates U.S. Clinical Trial Of Apograft

Thu 22nd October, 2020 1:09pm
Oct 22 (Reuters) - Cellect Biotechnology Ltd  APOP.O :
    * CELLECT BIOTECHNOLOGY INITIATES U.S. CLINICAL TRIAL OF
APOGRAFT
    * CELLECT BIOTECHNOLOGY LTD - INITIATED CLINICAL TRIAL IN
U.S. TO
DETERMINE SAFETY &TOLERABILITY OF APOGRAFT TECHNOLOGY FOR BONE
MARROW TRANSPLANTATIONS
    * CELLECT BIOTECHNOLOGY LTD - TRIAL WILL ENROLL 18 PATIENTS

Source text for Eikon:  ID:nGNX64VRND 
Further company coverage:  APOP.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.